Overview

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.
Phase:
Phase 3
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated